Tags

Type your tag names separated by a space and hit enter

Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
Parkinsonism Relat Disord. 2009 May; 15(4):287-94.PR

Abstract

Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD). A systematic literature search was conducted through April 2007. Both efficacy and safety endpoints were evaluated. DA monotherapy showed superior efficacy but more frequent adverse events compared to placebo. In addition, DA demonstrated inferior efficacy to levodopa, but was associated with fewer motor complications. However, DAs were associated with a greater incidence of nuisance side effects, such as hallucinations, somnolence and dizziness. The use of DA is an effective treatment option for the treatment of early PD and appears especially useful among PD patients with wearing-off phenomenon or dyskinesias on levodopa; however it may result in more adverse events and higher withdrawal rates.

Authors+Show Affiliations

School of Pharmacy, University of Connecticut, CT, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18774743

Citation

Baker, William L., et al. "Dopamine Agonists in the Treatment of Early Parkinson's Disease: a Meta-analysis." Parkinsonism & Related Disorders, vol. 15, no. 4, 2009, pp. 287-94.
Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord. 2009;15(4):287-94.
Baker, W. L., Silver, D., White, C. M., Kluger, J., Aberle, J., Patel, A. A., & Coleman, C. I. (2009). Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism & Related Disorders, 15(4), 287-94. https://doi.org/10.1016/j.parkreldis.2008.07.004
Baker WL, et al. Dopamine Agonists in the Treatment of Early Parkinson's Disease: a Meta-analysis. Parkinsonism Relat Disord. 2009;15(4):287-94. PubMed PMID: 18774743.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. AU - Baker,William L, AU - Silver,Dee, AU - White,C Michael, AU - Kluger,Jeffrey, AU - Aberle,Jeffrey, AU - Patel,Aarti A, AU - Coleman,Craig I, Y1 - 2008/09/06/ PY - 2008/03/06/received PY - 2008/07/16/revised PY - 2008/07/18/accepted PY - 2008/9/9/pubmed PY - 2009/8/11/medline PY - 2008/9/9/entrez SP - 287 EP - 94 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 15 IS - 4 N2 - Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD). A systematic literature search was conducted through April 2007. Both efficacy and safety endpoints were evaluated. DA monotherapy showed superior efficacy but more frequent adverse events compared to placebo. In addition, DA demonstrated inferior efficacy to levodopa, but was associated with fewer motor complications. However, DAs were associated with a greater incidence of nuisance side effects, such as hallucinations, somnolence and dizziness. The use of DA is an effective treatment option for the treatment of early PD and appears especially useful among PD patients with wearing-off phenomenon or dyskinesias on levodopa; however it may result in more adverse events and higher withdrawal rates. SN - 1873-5126 UR - https://www.unboundmedicine.com/medline/citation/18774743/Dopamine_agonists_in_the_treatment_of_early_Parkinson's_disease:_a_meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(08)00216-2 DB - PRIME DP - Unbound Medicine ER -